M. Sherman

Hepatology · 2001–2016

A researcher in the Science corpus: 11 papers; trusts 6 researchers and is trusted by 14 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 221 citations into it; #12 of 151 by trust here, #13 by citations
• Epidemiology — 129 citations into it; #283 of 2,148 by trust here, #227 by citations
• Surgery — 76 citations into it
• Pathology and Forensic Medicine — 28 citations into it

Whom M. Sherman trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Llovet
2. Jordi Bruix1 , 2
3. R. Poon
4. Riccardo Lencioni
5. A. Cheng
6. C. Lo

Who trusts M. Sherman overall

1. Jordi Bruix1 , 2
2. J. Llovet
3. Amit G. Singal
4. R. Salem
5. N. Chalasani
6. Riccardo Lencioni
7. J. Heimbach
8. L. Kulik
9. Alejandro Forner1 , 2

Papers from M. Sherman's perspective

Ordered by how strongly the researchers M. Sherman trusts endorse each paper. Same corpus, a different order for every researcher.

1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
2. Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
3. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
4. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. (American Journal of Epidemiology)
5. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
6. Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (Annals of Surgery)
7. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
8. Hepatocellular carcinoma pathogenesis: from genes to environment (Nature Reviews. Cancer)
9. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (Journal of Hepatology)
10. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. (The Lancet)

Their papers

• Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. (2016) — 1,557 citations
• Hepatocellular carcinoma (2016) — 1,645 citations
• Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study (2015) — 1,194 citations
• Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. (2013) — 774 citations
• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (2012) — 790 citations
• Management of hepatocellular carcinoma: An update (2011) — 8,421 citations
• Design and endpoints of clinical trials in hepatocellular carcinoma. (2008) — 1,196 citations
• Management of hepatocellular carcinoma (2005) — 3,455 citations
• Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. (2003) — 889 citations
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (2001) — 4,137 citations
• Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis (2001) — 671 citations